CITIC Capital offers to buy China Biologic for $110 per share: Reuters

A unit of Chinese investment firm CITIC Capital Holdings Ltd said on Monday it has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc (CBPO.O), in a deal valuing the company at $3.65 billion.

DealsNorth AmericaUSHealthcareBriefs